Abstract:Aldose Reductase (AR) reduces a variety of substrates, such as aldehydes, aldoses and corticosteroids. It is the first and rate-limiting enzyme of the polyol pathway and is an important target enzyme for diabetes-associated complications, including retinopathy, neuropathy, and nephropathy. Inhibitors targeting this enzyme are structurally different and some of them have side effects. In existing publications, computational techniques are applied to investigate the binding affinities of existing inhibitors and predicting the affinities of newly designed ligands. However, these calculations only employ coarse and approximated methods such as docking and MM/PBSA. Brute force simulations are employed to study the dynamics of the system but no converged statistics is obtained. As a result, these computations provide results not consistent with experimental values and large discrepancies exist. In the current work, we employ the enhanced sampling technique of alchemical free energy simulation to calculate the binding affinities of several ligands targeting AR. The statistical error is defined with care and the correlation in the time-series data is fully considered. The statistically optimal estimators are used to extract the free energy estimates and the predicted results are in agreement with the experimental values. Less computationally demanding end-point free energy methods are also performed to compare their efficiency with the alchemical methods. As is expected, the end-point methods are of less accuracy and reliability compared with the alchemical free energy methods. The decomposition of the free energy difference in each alchemical transformation into the enthalpic and entropic components gives further insights on the thermodynamics. The enthalpy-entropy compensation is observed in this case. As the structural data obtained from experiments are only snapshots and more details are needed to understand the dynamics of the protein-ligand system, the conformational ensemble is analyzed. We identify important residues involved in the protein-ligand binding case and short-lived interactions formed due to fluctuations in the conformational ensemble. The current work shed light on the atomic detailed understanding of the dynamics of AR-inhibitors interactions.

Computational determination of binding structures and free energies of glucose 6-phosphate dehydrogenase with novel steroid inhibitors.

Inhibition Mechanism of Α-Glucosidase by Three Geranylated Compounds: Kinetic, Spectroscopic and Molecular Docking

Investigation of the Interaction Between Glucose-6-phosphate Dehydrogenase and ATA-inhibitor by Molecular Docking and Molecular Dynamics Simulation

Understanding Aldose Reductase-Inhibitors interactions with free energy simulation

Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Computational Revelation of Binding Mechanisms of Inhibitors to Endocellular Protein Tyrosine Phosphatase 1B Using Molecular Dynamics Simulations.

Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.

Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases

In silico single and double docking antioxidant and antidiabetic potential of EGCG and Bacoside-A

Computational analysis of dimer G6PD structure to elucidate pathogenicity of G6PD variants

Identification of potential modulators for human GPD1 by docking-based virtual screening, molecular dynamics simulations, binding free energy calculations, and DeLA-drug analysis

Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors

Three-Dimensional Quantitative Structure-Activity Relationship of 4,5,6,7-Tetrahydrothienopyridines Analogues As Glucose-6-Phosphatase Inhibitors

Revealing the binding modes and the unbinding of 14-3-3σ proteins and inhibitors by computational methods

Computer-Aided Designing Peptide Inhibitors of Human Hematopoietic Prostaglandin D2 Synthase Combined Molecular Docking and Molecular Dynamics Simulation

Molecular Docking, Pharmacophore Modeling, and ADMET Prediction of Novel Heterocyclic Leads as Glucokinase Activators

Steered Molecular Dynamics Study of Inhibitor Binding in the Internal Binding Site in Dehaloperoxidase-Hemoglobin.

Probing Ligand-Binding Modes and Binding Mechanisms of Benzoxazole-Based Amide Inhibitors with Soluble Epoxide Hydrolase by Molecular Docking and Molecular Dynamics Simulation.

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Molecular dynamics simulation and free energy calculation studies of Coagulin L as dipeptidyl peptidase-4 inhibitor